Sandoz to Pay Up to $77 Million for Three Biosimilar Drug Rights From Shanghai Henlius Biotech

3-line summary

• Sandoz agreed to pay up to $77 million for the rights to three biosimilar drugs from Shanghai Henlius Biotech, according to an Investing.com report.

This summary is our own processing of the source article; see the source link below for full context.